scholarly journals Populációalapú „pilot” colorectalis rákszűrés eredményessége. Csongrád megye, 2015

2017 ◽  
Vol 158 (42) ◽  
pp. 1658-1667
Author(s):  
Mariann Rutka ◽  
Tamás Molnár ◽  
Renáta Bor ◽  
Klaudia Farkas ◽  
Anna Fábián ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Blood Test ◽  
Screening Program ◽  
Participation Rate ◽  
Population Based ◽  
Screening Colonoscopy ◽  
Average Risk ◽  
Short Term ◽  
Term Efficacy ◽  
Colorectal Screening

Abstract: Introduction: In Hungary, a nationwide colorectal screening program is about to be introduced in order to improve the extremely high mortality rate of colorectal cancer (CRC). Aim: The aim of our study was to summarize experiences and assess short-term efficacy of the population-based pilot colorectal screening program in 2015 in Csongrád County, Hungary. Patients and method: Asymptomatic individuals between the ages of 50 and 70 with average risk of colorectal cancer participated in the program that was based on the two-step screening method (i.e. immune fecal blood test and colonoscopy). The short-term efficacy of the screening program was assessed as the change in total CRC incidence and initial tumor stage in the screening year (2015) compared to a control year (2013) in Szeged and its surroundings. Participation rate, positive predictive value of the screening methods and tumor detection rate was assessed. Results: 22,130 individuals were invited, the participation rate was 46.4%. Immune fecal blood test proved to be non-negative in 1,343 cases (13%), screening colonoscopy was performed in 766 of them (7.5%). Total colonoscopy was performed in 711 individuals. Based on the reports, adenoma was detected in 358 (50.3%) and malignancy in 42 (5.9%) individuals. In the background population, the incidence of colon cancer was significantly higher (183 vs. 228; p = 0.026) and was diagnosed at significantly earlier stage (p = 0.002). Lymph node involvement was significantly lower in 2015 (48.3% vs. 37.1%; p = 0.049). Conclusion: The Csongrád county population-based colorectal cancer screening was evidently successful on the short term considering participation rate, and the changes in CRC incidence and stage, thus its national extension is necessary. Orv Hetil. 2017; 158(42): 1658–1667.

Prevalence of advanced colorectal neoplasia according to risk categories at screening colonoscopy in a tertiary referral center.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 578-578
Author(s):  
Eduardo Negrete Carballo ◽  
Fidel David Huitzil Melendez
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Risk Stratification ◽  
Colorectal Neoplasia ◽  
Screening Colonoscopy ◽  
Average Risk ◽  
Moderate Risk ◽  
Advanced Colorectal Neoplasia ◽  
Advanced Neoplasm ◽  
Colorectal Screening

578 Background: Colorectal cancer (CRC) is the third most common cancer in the world. There is strong evidence that screening for colorectal cancer improves survival in conutries with high incidence. Although Mexico is considered a country with a low incidence of CRC, 4694 potentially preventable deaths occur every year. There is no established CRC screening program in our country, risk stratification of the target populations to be screened may bring potential advantages, making the strategy more cost-effective. The Asia-Pacific Colorectal Screening (APCS) score, is a validated risk-stratification tool that helps identify individuals at risk for advanced colorectal neoplasm amongst the asymptomatic population. Methods: We performed a retrospective, cross-sectional analysis of database records from 1172 patients who underwent screening colonoscopy betwen january 2013 and november 2014. Results: The prevalence of advanced colorectal neoplasia was 2.9%. Applying the APCS stratification, 91 subjects (7.8%) were in the average risk tier, 849 subjects (72.4%) in the moderate risk tier and 232 (19.8%) subjects in the high risk tier. The prevalence of advanced neoplasia in the average risk, moderate risk and high risk groups was 0%, 2.6% and 5.1%, respectively. The subjects in the high risk tier had 2.21-fold (p = 0.021) increased prevalence of advanced neoplasia than those in the average-moderate tier. Conclusions: The APCS score is a simple risk stratification index for colorectal advanced neoplasm that uses elementary clinical information on age, gender, family history and smoking to stratify the risk of colorectal advanced neoplasm in asymptomatic subjects for priority of colorectal screening.

Trends in screening for colorectal cancer in France

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1538-1538
Author(s):  
J. Viguier ◽  
A. Calazel Benque ◽  
M. Mahjoubi ◽  
X. Pivot ◽  
J. Morère ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Screening Program ◽  
Age Groups ◽  
Target Population ◽  
Population Based ◽  
Screening Programs ◽  
The Family ◽  
Objective Rate ◽  
Nationwide Observational Study ◽  
Colorectal Screening

1538 Background: In France, after a pilot population-based screening program in 23 districts (2002–2003), a national organized program was progressively implemented starting in 2005. The EDIFICE 2 survey was conducted in 2008, 3 years after EDIFICE 1, to provide a better understanding of French people's participation in colorectal screening programs and to assess the evolution between the two periods. Methods: This second nationwide observational study, EDIFICE 2, was conducted in January 2008 among a representative sample of 1,801 subjects aged between 40 and 85 years old. The analysis focused on the target population of the national screening program (50–74 years old). Results: In 2008, 38% of subjects between 50 and 74 years (N = 928) had undergone a screening test for colorectal cancer (including fecal test or colonoscopy) versus 25% in 2005 (p < 0.05); 32% of the unscreened population (N = 575) planned to undergo a test. Colorectal cancer screening increased significantly in all age groups, especially between 65 and 69 years, and for both sexes. A most significant increase can be observed in districts with pilot programme (+ 21%). Factors influencing the probability of screening were: being encouraged by the family circle, living in a couple, the existence of a case of cancer (especially colorectal cancer) in the family circle, and fear of colorectal cancer. The main reasons for not performing the screening were: not feeling concerned, no recommendation by the GP, carelessness, no symptoms, and fear of exams or results. Conclusions: The objective rate of participation (50%), can be reached by motivating the unscreened population already planning to perform a test. The results in the pilot districts show the effectiveness of an organization of the screening. This trend of increasing testing will probably be confirmed in the future if the reasons for non-attendance in an organized program are addressed. No significant financial relationships to disclose.

scholarly journals Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Neal Shahidi ◽  
Laura Gentile ◽  
Lovedeep Gondara ◽  
Jeremy Hamm ◽  
Colleen E. McGahan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Screening Program ◽  
Population Based ◽  
Fecal Immunochemical Test ◽  
Average Risk ◽  
Health Authorities ◽  
Cancer Screening Program ◽  
Immunochemical Test ◽  
A Prospective Study ◽  
The Cost

Background and Aims. The Canadian Partnership Against Cancer (CPAC) recommends a fecal immunochemical test- (FIT-) positive predictive value (PPV) for all adenomas of ≥50%. We sought to assess FIT performance among average-risk participants of the British Columbia Colon Screening Program (BCCSP).Methods.From Nov-2013 to Dec-2014 consecutive participants of the BCCSP were assessed. Data was obtained from a prospectively collected database. A single quantitative FIT (NS-Plus, Alfresa Pharma Corporation, Japan) with a cut-off of ≥10 μg/g (≥50 ng/mL) was used.Results. 20,322 FIT-positive participants underwent CSPY. At a FIT cut-off of ≥10 μg/g (≥50 ng/mL) the PPV for all adenomas was 52.0%. Increasing the FIT cut-off to ≥20 μg/g (≥100 ng/mL) would increase the PPV for colorectal cancer (CRC) by 1.5% and for high-risk adenomas (HRAs) by 6.5% at a cost of missing 13.6% of CRCs and 32.4% of HRAs.Conclusions.As the NS-Plus FIT cut-off rises, the PPV for CRC and HRAs increases but at the cost of missed lesions. A cut-off of ≥10 μg/g (≥50 ng/mL) produces a PPV for all adenomas exceeding national recommendations. Health authorities need to take into consideration endoscopic resources when selecting a FIT positivity threshold.

scholarly journals Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain)

2021 ◽  
pp. 106929
Author(s):  
Vives Nuria ◽  
Binefa Gemma ◽  
Vidal Carmen ◽  
Milà Núria ◽  
Muñoz Rafael ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Screening Program ◽  
Population Based ◽  
Short Term

scholarly journals Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain)

2021 ◽  
Author(s):  
Vives Nuria ◽  
Binefa Gemma ◽  
Vidal Carmen ◽  
Milà Núria ◽  
Muñoz Rafael ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Perceived Risk ◽  
Screening Program ◽  
Waiting Times ◽  
Population Based ◽  
Emotional Wellbeing ◽  
Short Term ◽  
Crc Screening ◽  
Screening Participation ◽  
Mean Time

Abstract Background By mid-March 2020, colorectal cancer (CRC) screening program in Catalonia was suspended at all levels. Our goal was to assess the short-term impact of the COVID-19 pandemic at a FIT-based CRC screening hub in the metropolitan area of Barcelona. Methods Short-term impact was measured in individuals invited between 1 January and 12 March 2020: screening participation, colonoscopy adherence, interval from positive test result to colonoscopy and psychological distress. Results Lockdown with the first wave of COVID-19 caused 111,000 individuals to defer their screening invitations. Participation among invitees between January - March 2020 was 39.3% (95% CI: 38.9–39.7), a decrease of 5% in comparison with the 41.4% (95% CI: 41.2–41.6) participation in 2019. Adherence to colonoscopy decreased from 89.3% (95% CI: 88.4–90.2) in 2019 to 81.4% (95% CI: 78.9–83.7) in the first quarter of 2020. The mean time to colonoscopy after resumption was 128.7 days (CI 95%: 125.3–132.2). Irrespective of test results, factors associated with higher levels of distress were a greater perceived risk of CRC and greater impairment of emotional wellbeing due to COVID-19. Conclusions The short-term impact of COVID-19 on CRC screening seems to have been modest, with a slight decrease in participation, a moderate decrease in colonoscopy adherence, and lengthened waiting times. However, a marked impact on future CRC incidence and deaths could be expected. Thus, it is critical to revert participation and colonoscopy adherence rates to that previously achieved while reducing the 5-month delay in screening invitations.

scholarly journals Comparison of One versus Two Fecal Immunochemical Tests in the Detection of Colorectal Neoplasia in a Population-Based Colorectal Cancer Screening Program

2016 ◽  
Vol 2016 ◽  
pp. 1-5
Author(s):  
Sarvenaz Moosavi ◽  
Robert Enns ◽  
Laura Gentile ◽  
Lovedeep Gondara ◽  
Colleen McGahan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Screening Program ◽  
Colorectal Neoplasia ◽  
Population Based ◽  
Added Value ◽  
Average Risk ◽  
Significance Level ◽  
Cancer Screening Program ◽  
Canadian Population

Objective.To determine the positive predictive value (PPV) of two versus one abnormal FIT in the detection of colorectal neoplasia in a Canadian population.Methods.Three communities enrolled in a colorectal cancer (CRC) screening pilot program from 01/2009 to 04/2013 using 2 FITs. Data collected included demographics, colonoscopy, pathology, and FIT results. Participants completed both FITs and had one positive FIT and colonoscopy. PPV of one versus two abnormal FITs was calculated using a weighted-generalized score statistic. A two-sided 5% significance level was used.Results.1576 of 17,031 average-risk participants, 50–75 years old, had a positive FIT. Colonoscopy revealed 58 (3.7%) cancers, 419 (31.6%) high-risk polyps, and 374 (23.7%) low-risk polyps as the most significant lesion. PPV of one versus two positive FITs for cancer, high-risk polyps, and any neoplasia were 1% versus 8%, 20% versus 40%, and 48% versus 67%, respectively (pvalue < 0.0001). When the first FIT was negative, the second positive FIT detected 7 CRCs and 98 high-risk polyps.Conclusions.PPV of two positive FITs is superior to one positive FIT for CRC and high-risk polyps. The added value of the second FIT was 12% of total CRCs and 23% of total high-risk polyps.

scholarly journals Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity

2021 ◽  
Vol 11 (6) ◽  
pp. 497
Author(s):  
Yoonsuk Jung ◽  
Eui Im ◽  
Jinhee Lee ◽  
Hyeah Lee ◽  
Changmo Moon
Keyword(s):  
Colorectal Cancer ◽  
Large Scale ◽  
Screening Program ◽  
Antiplatelet Agents ◽  
Population Based ◽  
Small Sample ◽  
Antithrombotic Agents ◽  
Predictive Values ◽  
Prescription Rates ◽  
Small Sample Sizes

Previous studies have evaluated the effects of antithrombotic agents on the performance of fecal immunochemical tests (FITs) for the detection of colorectal cancer (CRC), but the results were inconsistent and based on small sample sizes. We studied this topic using a large-scale population-based database. Using the Korean National Cancer Screening Program Database, we compared the performance of FITs for CRC detection between users and non-users of antiplatelet agents and warfarin. Non-users were matched according to age and sex. Among 5,426,469 eligible participants, 768,733 used antiplatelet agents (mono/dual/triple therapy, n = 701,683/63,211/3839), and 19,569 used warfarin, while 4,638,167 were non-users. Among antiplatelet agents, aspirin, clopidogrel, and cilostazol ranked first, second, and third, respectively, in terms of prescription rates. Users of antiplatelet agents (3.62% vs. 4.45%; relative risk (RR): 0.83; 95% confidence interval (CI): 0.78–0.88), aspirin (3.66% vs. 4.13%; RR: 0.90; 95% CI: 0.83–0.97), and clopidogrel (3.48% vs. 4.88%; RR: 0.72; 95% CI: 0.61–0.86) had lower positive predictive values (PPVs) for CRC detection than non-users. However, there were no significant differences in PPV between cilostazol vs. non-users and warfarin users vs. non-users. For PPV, the RR (users vs. non-users) for antiplatelet monotherapy was 0.86, while the RRs for dual and triple antiplatelet therapies (excluding cilostazol) were 0.67 and 0.22, respectively. For all antithrombotic agents, the sensitivity for CRC detection was not different between users and non-users. Use of antiplatelet agents, except cilostazol, may increase the false positives without improving the sensitivity of FITs for CRC detection.

scholarly journals Role of community pharmacies in a population-based colorectal cancer screening program

2021 ◽  
pp. 106420
Author(s):  
Nuria Vives ◽  
Núria Milà ◽  
Gemma Binefa ◽  
Noemie Travier ◽  
Albert Farre ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Screening ◽  
Colorectal Cancer Screening ◽  
Screening Program ◽  
Population Based ◽  
Community Pharmacies ◽  
Cancer Screening Program
Sign in / Sign up

Export Citation Format

Share Document